BACKGROUND: Cardiac hypertrophy is an adaptive response to increased workload that, if unrelieved, leads to heart failure. It has been reported that cardiomyocyte apoptosis contributes to failure, and that vascular endothelial growth factor (VEGF) treatment of hypertrophied myocardium increases capillary density and improves myocardial perfusion. In this study we hypothesized that VEGF treatment reduces cardiomyocyte apoptosis and thereby preserves myocardial contractile function. METHODS AND RESULTS: Newborn rabbits underwent aortic banding. At 4 and 6 weeks of age, hypertrophied animals were treated with intrapericardial administration of recombinant VEGF protein. Three groups of animals were investigated: age-matched controls (C), untreated hypertrophied (H), and VEGF-treated hypertrophied hearts (T). Cardiomyocyte apoptosis was determined by TUNEL staining and PARP cleavage (immunoblotting of nuclear extracts) and cardiac function by transthoracic echocardiography. Death attributable to severe heart failure occurred in 14 of 43 untreated and 2 of 29 VEGF-treated animals (P<0.01). TUNEL-positive cardiomyocyte nuclei (n/1000 nuclei) were significantly increased in untreated hearts at 5 weeks (H: 10+/-1.8 versus T: 3+/-0.7) and at 7 weeks (H: 13+/-3.6 versus T: 5+/-1.5; P<0.05). Increased apoptosis in untreated hypertrophy was also confirmed by the presence of PARP cleavage (H: 74+/-7 versus T: 41+/-4 arbitrary densitometry units; P<0.05). VEGF treatment preserved left ventricular mass, prevented dilation (T: 1.01+/-0.06 versus H: 0.77+/-0.07; P<0.05), and preserved contractility indices compared with untreated hearts. CONCLUSIONS: Lack of adaptive capillary growth impairs myocardial perfusion and substrate delivery in hypertrophying myocardium. VEGF treatment reduces myocardial apoptosis and prolongs survival in a model of severe progressive left ventricular hypertrophy. Promoting capillary growth with VEGF reduces apoptosis, preserves myocardial contractile function, and delays the onset of failure in pressure-loaded infant myocardium.
BACKGROUND:Cardiac hypertrophy is an adaptive response to increased workload that, if unrelieved, leads to heart failure. It has been reported that cardiomyocyte apoptosis contributes to failure, and that vascular endothelial growth factor (VEGF) treatment of hypertrophied myocardium increases capillary density and improves myocardial perfusion. In this study we hypothesized that VEGF treatment reduces cardiomyocyte apoptosis and thereby preserves myocardial contractile function. METHODS AND RESULTS: Newborn rabbits underwent aortic banding. At 4 and 6 weeks of age, hypertrophied animals were treated with intrapericardial administration of recombinant VEGF protein. Three groups of animals were investigated: age-matched controls (C), untreated hypertrophied (H), and VEGF-treated hypertrophied hearts (T). Cardiomyocyte apoptosis was determined by TUNEL staining and PARP cleavage (immunoblotting of nuclear extracts) and cardiac function by transthoracic echocardiography. Death attributable to severe heart failure occurred in 14 of 43 untreated and 2 of 29 VEGF-treated animals (P<0.01). TUNEL-positive cardiomyocyte nuclei (n/1000 nuclei) were significantly increased in untreated hearts at 5 weeks (H: 10+/-1.8 versus T: 3+/-0.7) and at 7 weeks (H: 13+/-3.6 versus T: 5+/-1.5; P<0.05). Increased apoptosis in untreated hypertrophy was also confirmed by the presence of PARP cleavage (H: 74+/-7 versus T: 41+/-4 arbitrary densitometry units; P<0.05). VEGF treatment preserved left ventricular mass, prevented dilation (T: 1.01+/-0.06 versus H: 0.77+/-0.07; P<0.05), and preserved contractility indices compared with untreated hearts. CONCLUSIONS: Lack of adaptive capillary growth impairs myocardial perfusion and substrate delivery in hypertrophying myocardium. VEGF treatment reduces myocardial apoptosis and prolongs survival in a model of severe progressive left ventricular hypertrophy. Promoting capillary growth with VEGF reduces apoptosis, preserves myocardial contractile function, and delays the onset of failure in pressure-loaded infant myocardium.
Authors: E Teiger; V D Than; L Richard; C Wisnewsky; B S Tea; L Gaboury; J Tremblay; K Schwartz; P Hamet Journal: J Clin Invest Date: 1996-06-15 Impact factor: 14.808
Authors: J W Adams; Y Sakata; M G Davis; V P Sah; Y Wang; S B Liggett; K R Chien; J H Brown; G W Dorn Journal: Proc Natl Acad Sci U S A Date: 1998-08-18 Impact factor: 11.205
Authors: Ingeborg Friehs; Adrian M Moran; Christof Stamm; Yeong-Hoon Choi; Douglas B Cowan; Francis X McGowan; Pedro J del Nido Journal: Ann Thorac Surg Date: 2004-06 Impact factor: 4.330
Authors: Ingeborg Friehs; Douglas B Cowan; Yeong-Hoon Choi; Kendra M Black; Reanne Barnett; Manoj K Bhasin; Christian Daly; Simon J Dillon; Towia A Libermann; Francis X McGowan; Pedro J del Nido; Sidney Levitsky; James D McCully Journal: Am J Physiol Heart Circ Physiol Date: 2012-12-21 Impact factor: 4.733
Authors: Indroneal Banerjee; Jianlin Zhang; Thomas Moore-Morris; Stephan Lange; Tao Shen; Nancy D Dalton; Yusu Gu; Kirk L Peterson; Sylvia M Evans; Ju Chen Journal: Circ Res Date: 2011-12-08 Impact factor: 17.367
Authors: Cody N Justice; Mohamed H Derbala; Tesla M Baich; Amber N Kempton; Aaron S Guo; Thai H Ho; Sakima A Smith Journal: J Cardiovasc Pharmacol Ther Date: 2018-04-29 Impact factor: 2.457
Authors: Indroneal Banerjee; John W Fuseler; Colby A Souders; Stephanie L K Bowers; Troy A Baudino Journal: Microsc Microanal Date: 2009-08-27 Impact factor: 4.127
Authors: Ekaterina V Fomicheva; Immanuel I Turner; Terri G Edwards; Janet Hoff; Eric Arden; Louis G D'Alecy; Joseph M Metzger Journal: Mol Ther Date: 2008-06-24 Impact factor: 11.454